Your browser doesn't support javascript.
loading
A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
Hamada, Kazuyuki; Yoshimura, Kiyoshi; Oshinomi, Kazuhiko; Hirasawa, Yuya; Ariizumi, Hirotsugu; Ohkuma, Ryotaro; Shida, Midori; Kubota, Yutaro; Matsui, Hiroto; Ishiguro, Tomoyuki; Sambe, Takehiko; Ishida, Hiroo; Horiike, Atsushi; Wada, Satoshi; Iwamoto, Sanju; Uchida, Naoki; Ogawa, Yoshio; Kobayashi, Shinichi; Tsunoda, Takuya.
Affiliation
  • Hamada K; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Yoshimura K; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Oshinomi K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Hirasawa Y; Department of Urology, Showa University School of Medicine, Tokyo, Japan.
  • Ariizumi H; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Ohkuma R; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Shida M; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Kubota Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Matsui H; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Ishiguro T; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Sambe T; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Ishida H; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Horiike A; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Wada S; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Iwamoto S; Department of Medicine, Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan.
  • Uchida N; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa University, Tokyo, Japan.
  • Ogawa Y; Division of Physiology and Pathology, Department of Pharmacology, Toxicology and Therapeutics, Showa University School of Pharmacy, Tokyo, Japan.
  • Kobayashi S; Department of Pharmacology, Showa University School of Medicine, Tokyo, Japan.
  • Tsunoda T; Department of Urology, Showa University School of Medicine, Tokyo, Japan.
Medicine (Baltimore) ; 101(2): e28339, 2022 Jan 14.
Article in En | MEDLINE | ID: mdl-35029177
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Urinary Bladder Neoplasms / Antibodies, Monoclonal, Humanized / Immune Checkpoint Inhibitors Type of study: Prognostic_studies Limits: Aged / Female / Humans Language: En Journal: Medicine (Baltimore) Year: 2022 Type: Article Affiliation country: Japan
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Urinary Bladder Neoplasms / Antibodies, Monoclonal, Humanized / Immune Checkpoint Inhibitors Type of study: Prognostic_studies Limits: Aged / Female / Humans Language: En Journal: Medicine (Baltimore) Year: 2022 Type: Article Affiliation country: Japan